SmartZyme Biopharma is a New York and San Diego based biopharmaceutical company focusing on therapeutic protein, enzyme, and mRNA engineering with ambitions to become a new global player in both the established and emerging markets. OrbiMed functions as our lead investor and adviser fueling the larger vision to expand through both organic discovery programs and thoughtful business development strategy. SmartZyme has already successfully developed next-generation therapeutic molecules in the diabetes and hematological spaces. Our pipeline is not bound by indication – we endeavor to develop market-changing products across a spectrum of unmet medical needs.
SmartZyme’s lead drug candidate generation technology was developed in-house and efficiently combines advanced protein engineering methods with the tools to select a single optimal drug candidate from up to 1,000,000,000 variants for any given drug program. SmartZyme’s selection process involves screening variants across over two dozen dimensions simultaneously, ensuring no single aspect of the candidate drug’s profile is diminished as part of the effort to deliver therapeutics with improved overall characteristics.
Our management team has extensive experience in starting and growing companies in the biopharmaceutical field and our Board of Directors is a group of well-known industry veterans.